- A Phase 2 clinical trial assessing BIND Therapeutics' (BIND -1.4%) investigational BIND-014, an ACCURIN drug candidate containing the chemo agent docetaxel, in patients with chemo-naive metastatic castration-resistant prostate cancer (mCRPC) met its primary efficacy endpoint with 71% of patients achieving radiographic progression-free survival (rPFS) for at least six months. The data were presented today at the 2016 Genitourinary Cancers Symposium in San Francisco.
- Despite the encouraging results, the company is terminating further development of BIND-014 for mCRPC, preferring to focus its resources on non-small cell lung cancer (the Phase 2 iNSITE 1 trial) and multiple tumor types (urothelial carcinoma, cholangiocarcinoma, cervical cancer, squamous cell carcinoma of the head and neck)(the Phase 2 iNSITE 2 trial).